Support Options

Submit a Support Ticket


Illinois BioNanotechnology Seminar Series Fall 2011: Precisely Size Controlled Drug-silica Nanoconjugate for Cancer Therapy

By Li Tang

University of Illinois at Urbana-Champaign

View Resource (HTM)

Licensed according to this deed.

Published on


Drug delivery nanomedicine, exemplified by micelles and nanoparticles roughly in the size range of 1-200 nm, have attracted much interest in the past 2-3 decades as alternative modalities for cancer treatment. The size of these drug delivery vehicles has been strongly correlated with their in vivo biodistribution, penetration in tumor tissue, and intracellular trafficking. It potentially has significant impact on their antitumor efficacy. However, it is challenging to make nanomedicine in large quanti-ties with controlled particle size and narrow particle size ranges, in particular for nanomedicine smaller than 50 nm. Here we report a novel drug delivery platform based on drug-silica nanoconju-gates (drug-NCs) that can be controlled fabricated at nearly any desired size between 20 and 200 nm, with extremely narrow particle size distribution, in multi-gram scale within a few hours. Several in vitro and in vivo studies demonstrated that the sizes of the drug-NCs have huge impact on cell uptake and tumor penetration; the drug-NCs with size of 20 nm outperform their counterparts with larger sizes, showing great promise in cancer therapy and diagnosis.


Li Tang, Department of Materials Science and Engineering


NCN@Illinois Laura Miller Omar Sobh Zuhaib Sheikh Nahil Sobh

Sponsored by


Zuhaib Bashir Sheikh

University of Illinois at Urbana-Champaign

Tags, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.